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Purpose: We reviewed our initial thoracic aorta (TA) stent graft experience in 28 patients from the perspective of treatment
with homemade devices (Dacron over Gianturco Z stents; 14 cases) and a commercial device (Excluder; W.L. Gore Co,
Flagstaff, Ariz; 14 cases).
Methods: From November 1996 to August 2001, 28 patients with a spectrum of disease (degenerative aneurysm, n  18;
chronic dissection, n  4; pseudoaneurysm, n  3, with 1 trauma and 2 anastomotic; intramural hematoma, n  2; and
coarctation, n  1) underwent TA stent grafting. Clinical parameters included a mean age of 71 years, 12 female (43%)
and 16 male (57%) patients, 14 of 28 patients (50%) with major comorbidities that prohibited open repair, and nine of
28 patients (32%) with urgent or ruptured conditions. Seven patients (25%) needed open surgical access to the aorta or
iliac artery for either concomitant abdominal aortic aneurysm repair (n  3) or device deployment (n  4), and six of 28
patients (21%) needed left subclavian-carotid transposition to provide for an adequate proximal fixation site. Focal (<15
cm) grafts were used in 19 patients, and the remaining patients had at least two thirds of their descending aorta excluded.
Results: The procedural mortality rate was 3.5% (1/28 patients); three additional deaths, (1 device-related) occurred
during the mean follow-up period of 17 months. Access artery complications occurred in six of 28 patients (21%), with
one fatal. No immediate or late open conversions were performed. One patient needed urgent dilation and stenting of a
collapsed stent graft 3 weeks after deployment. Serious systemic complications included temporary dialysis (n  1),
congestive heart failure (n 1), and unstable angina (n 1). Complete exclusion of the TA lesion was noted in 27 of 28
cases (96%). No cases of spinal cord ischemia were noted. Ease and accuracy of deployment was superior for the second
generation (commercial) device.
Conclusion: TA stent graft repair, although in evolution, appears to be a safe and effective alternative to open repair for
many patients with a spectrum of TA disease. Prospective trials for individual diseases will be necessary to define its
ultimate role. (J Vasc Surg 2002;35:1129-36.)
Stent graft repair of thoracic aortic (TA) aneurysm, first
reported by Dake et al,1 has progressed more slowly than
the corresponding experience with infrarenal aneurysm.
The much lower incidence rate of degenerative aneurysm in
the TA and the device design constraints imposed by the
need for proportionally larger devices inserted from more
remote access sites are plausible explanations for this trend.
However, the perspective of offering a less invasive form of
treatment for lesions that affect the descending TA is an
appropriate one because conventional repair thereof re-
mains a major surgical undertaking with mortality and
serious morbidity rates in the 5% to 10% range, even in
centers with considerable experience.2,3 In addition, the
spectrum of TA disease, including degenerative aneurysm,
acute and chronic dissection, penetrating ulcer, intramural
hematoma, and traumatic aortic tear, is potentially amena-
ble to stent graft repair and will likely increase demands for
this technology in the future.
Both device evolution and clinical experience with dif-
ferent diseases in TA stent graft repair remain at an early
stage. Only a single large clinical series has been reported,
with the acknowledged limitation imposed by first genera-
tion devices wherein device-related problems and compli-
cations were common.4 Herein, we report our initial expe-
rience with TA stent graft repair with a perspective gained
from use of both custom-made constructs and a commer-
cially made device (Excluder; W.L. Gore Co, Flagstaff,
Ariz) currently in phase II clinical trials.
PATIENTS AND METHODS
During the interval from November 1996 to August
2001, 28 patients underwent stent graft repair of TA le-
sions. Use of custom-made devices (see subsequent) was
originally sanctioned on a case-by-case basis by the Massa-
chusetts General Hospital Institutional Review Board
(IRB); subsequent use of this construct as standard of care
was approved. Fourteen patients underwent treatment with
a commercially manufactured device (Excluder) with two
separate clinical circumstances. Eleven patients were en-
rolled in a US Food and Drug Administration-approved,
industry-sponsored phase II clinical trial (with informed
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consent) approved by the IRB. This trial compares the
Gore Excluder to open repair, and for eligibility, patients
had to be candidates for either procedure. Three patients
who underwent treatment with the Excluder device had
conditions managed on a “compassionate use” basis be-
cause they did not meet clinical or anatomic criteria for the
phase II trial. Such use was sanctioned on an individual case
basis by the hospital IRB.
All patients underwent preoperative evalution with a
combination of fine-cut (3-mm) computed abdominal to-
mographic (CAT) scans that encompassed the entire TA
and abdominal aorta; helical three-dimensional reconstruc-
tions were used to supplement graft length measurements.
Transfemoral angiography with a 100-cm marker catheter
was used in all patients for optimal visualization of arch
anatomy, as the principle guide to device length, and for
evaluation of the iliofemoral access arteries. Aortic diame-
ters at the proximal and distal fixation sites were assessed on
an outer wall to outer wall basis from the axial and recon-
structed CAT scan images. Two centimeters of proximal
and distal (proximal to the celiac axis) fixation sites with
diameters therein not exceeding 37 mm were the minimum
anatomic criteria to permit stent grafting. Proximal fixation
length could be increased with subclavian transposition.
Graft diameter was selected with oversizing 10% to 15% of
the fixation site diameter. Qualitative assessment of the
stent graft landing sites (aortic wall calcification or athero-
thrombotic debris) was assessed from precontrast and post-
contrast CAT scan results.
Stent graft designs. Two different graft constructs
were used. The first was a custom-made device comprised
of an endoskeleton of self-expanding Gianturco Z stents
(W.A. Cook, Inc, Bloomington, Ind) covered with an
ironed (to eliminate graft crimping) woven Dacron graft
(Cooley Veri-soft, Meadox Medicals, Inc, Oakland, NJ) as
originally described by Dake et al.1 Graft material extended
to the ends of the endoskeleton from which the attachment
barbs were removed. The interlocking 2.5-cm lengths of
the Z stents were affixed to each other with 4-0 nylon
sutures, and the graft material was attached to the en-
doskeleton with 5-0 polypropylene sutures placed through
the stent eyelets. Graft diameters for this construct ranged
from 20 mm (for a focal pseudoaneurysm at the site of a
prior coarctation repair) to a maximum of 34 mm (con-
strained by stent size and the delivery system.) Custom-
made grafts were gas sterilized the day before use and
loaded into the delivery system in the operating room. The
delivery system consisted of a 65 cm-long or 90 cm-long
24F Keller-Timmerman sheath (W.A. Cook, Inc), suffi-
ciently long to be positioned across the site of deployment.
The device was manually loaded into a 24F peel-away
sheath, which was used to introduce the device into the
delivery sheath. With flouroscopic observation, the device
was advanced inside the sheath and positioned across the
aneurysm. The device was deployed with fixing it in place
with the sheath obturator and simultaneously retracting the
sheath to release the self-expanding device. The other stent
graft construct was a commercially manufactured (W.L.
Gore, Co) device composed of a thin-walled polytetrafluo-
roethylene graft and a nitinol exoskeleton. The stent graft is
self-expanding to a maximum diameter of 40 mm and is
delivered through a sheath (22F or 24F) into the abdomi-
nal aorta to prevent both trauma to and premature deploy-
ment of the construct in passage through the iliofemoral
access arteries. Thereafter, the stent graft is advanced “bare-
back” over a guidewire and is deployed essentially instan-
taneously from its midportion to either end with release of
an enveloping thin membrane.
Operative technique. Procedures were performed
either in the operating room or in an operating room
compatible suite in the vascular radiology department.
General anesthesia with arterial line monitoring was used in
all cases and, in cases in which the stent graft was carried to
the distal aortic arch, patients were positioned with shoul-
ders rotated in right lateral decubitus position with the hips
flat facilitating imaging in a steep left anterior oblique
projection. Twenty patients (71%) could be approached
with open femoral artery access, and in these cases, con-
tralateral percutaneous femoral access was used for control
and angiographic catheter access. Intraoperative imaging
guidance was with standard catheter angiography per-
formed after the stent grafts had been positioned in the
approximate area of deployment. Four patients underwent
open access via the abdominal aorta; three of these under-
went simultaneous open repair of abdominal aortic aneu-
rysm (AAA). In these circumstances, graft repair of infrare-
nal (1 case) or suprarenal (2 cases) AAA were performed in
standard fashion, and thereafter, a 10-mm Dacron sidearm
graft was anastomosed to the abdominal aortic graft for the
stent graft delivery system access. Similarly, four patients
underwent access with an initial iliac “chimney” graft
(10-mm Dacron) performed through a lower abdominal
retroperitoneal incision. Pharmacologic afterload reduc-
tion to a systolic blood pressure in the 80 mm Hg range was
used before graft deployment only in circumstances in
which the proximal deployment site was located in the
aortic arch. Six patients (21%) needed a preliminary left
subclavian to common carotid transposition proximal to
the internal mammary artery to provide an adequate (2-cm
minimum) proximal neck for stent graft fixation in the mid
to distal aortic arch. This procedure was performed
through a supraclavicular incision as an initial staged ap-
proach 2 days before stent graft implantation. Nine patients
(32%) were cared for perioperatively in an intensive care
unit, although three of these needed such care because of
simultaneous open AAA repair; the remaining six patients
had planned intensive care unit stays because of comorbidi-
ties. Mean operative time (exclusive of concomitant AAA
repair) was 160 minutes (range, 70 to 490 minutes), and
blood loss in cases without open AAA repair averaged 600
mL (range, 50 to 4500 mL).
Patient clinical and anatomic profile. Twenty-eight
patients (12 female and 16 male) with an average 71 years
of age (range, 36 to 91 years) underwent treatment. Patho-
logic characteristics of the TA lesions are displayed in the
Table. Fourteen of 28 patients had major comorbidities (all
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cardiopulmonary) believed to preclude open repair. Nine
patients had undergone prior AAA graft repair. Nine pa-
tients (32%) underwent treatment in urgent circumstances,
with documented symptomatic expansion in four patients,
bronchopulmonary erosion in two patients, and contained
rupture in three patients. Treatment size threshold for
degenerative aneurysms was 6 cm.5,6 Twenty patients
(71%) had relatively focal disease amenable (in 19 of 20
cases) to single stent grafts not exceeding 15 cm in length.
The remaining eight patients had more extensive disease
that necessitated at least two interlocking stent grafts cov-
ering most or all of the descending aorta. One patient with
a type II thoracoabdominal aneurysm had combined open
abdominal and stent graft repair extending from the distal
arch to the aortic bifurcation, with the caudal end of the
stent graft deployed into the suture line of a suprarenal
AAA repair. Stent graft diameter requirements varied with
individual disease, with a minimum of 20 mm for unusual
disease, such as anastomotic pseudoaneurysm at the site of
prior coarctation repair. Sixteen patients (60%) needed
stent graft 34 mm or more in diameter, with two patients
needing 40-mm grafts (Fig).
RESULTS
Endografts were successfully deployed in all patients
with complete exclusion of the TA disease in 27 of 28
patients (96%). The single initial technical failure resulted
when proximal retrograde and distal aortic dissection oc-
curred during the course of stent graft repair of a symptom-
atic intramural hematoma of the proximal descending
aorta. This dissection channel has sealed on follow-up
imaging studies, although this patient also needed endo-
vascular fenestration and stent placement at the aortic
bifurcation to treat iliac artery obstruction resulting from
the iatrogenic dissection. No early or late open conversions
were necessary, and no graft migrations have been noted.
Endoleak was detected on either intraprocedural angiogra-
phy or CAT scan before discharge in six patients (21%)
(type I, ie, proximal attachments, 2 patients; type II, 3
patients; type III, ie, graft-graft junction, 1 patient). Yet
five of these six endoleaks that were recognized to be
quantitatively rather small sealed spontaneously within 1
month of surgery presumably because of otherwise satisfac-
tory graft positioning and apposition to the aortic wall
fixation sites. The single exception was a patient with a
small type II endoleak who died 4 months after treatment
of unrelated causes and in whom further imaging studies
were not obtained. No differences were found in the inci-
dence of early endoleak or aneurysm exclusion at last fol-
low-up examination between commercial grafts and cus-
tom-made constraints.
Mortality. A single periprocedural death (3.5%) oc-
curred in a 91-year-old patient treated for a symptomatic
contained rupture of a focal degenerative aneurysm. Dis-
ruption of the iliofemoral access artery (from a transfemoral
approach) caused substantial hemorrhage and needed im-
mediate open aortofemoral reconstruction. This patient
died of multisystem failure on postoperative day 12. Three
additional deaths have occurred during a mean follow-up
period of 17.8 months (range, 1 to 53 months). One of
these deaths was device related. An apparently successful
(commercial device) stent graft exclusion of a contained
rupture of a distal arch aneurysm failed when the patient
was seen in 10 months with massive hematemesis and an
aortoesophageal erosion was confirmed with endoscopy.
CAT scan results showed aortic rupture at both ends of the
stent graft, and enteric erosion/infection of the original
aneurysm sac was suspected. One patient died of myocar-
dial infarction at 10 months after surgery; the final death
(aspiration pneumonia) occurred 4 months after combined
open/stent graft repair of a symptomatic type II TA aneu-
rysm. Crude survival rate was accordingly 86% at a mean
follow-up interval of 18 months after stent graft repair.
Morbidity. No complications specifically related to
surgical transposition of the left subclavian artery occurred.
Stent graft procedural-related complications were classified
as either local or systemic. Local complications occurred in
eight patients (28%) and were usually (75%) related to the
iliofemoral access arteries; such access artery complications
are related to bulky introducer sheaths and occurred with
equal frequency throughout the study period and irrespec-
tive of stent graft design. Three patients needed either
pelvic laparotomy or retroperitoneal exposure of the iliac
artery for repair; three repairs could be accomplished with
extension of the original groin incision, and two postoper-
ative groin hematomas were managed conservatively.
White et al7 noted that 27% of their patients needed il-
iofemoral reconstructions for access artery complications.
Two device-related complications (both with custom-made
grafts) occurred and necessitated endovascular rescue pro-
cedures. One was the intraprocedural dissection detailed
previously, and a second patient had sudden kinking of a
custom stent graft originally placed for recurrent coarcta-
tion and suture line false aneurysm. This resulted in bilat-
eral lower extremity ischemia and was successfully managed
with placement of an uncovered stent within the original
stent graft. No significant groin wound infections were
noted.
Remote or systemic nonfatal complications occurred in
eight patients (28%) and included (all complications listed)
respiratory failure (n 3; two patients with major anteced-
ent pulmonary comorbidity), temporary dialysis (n  1),
atrial fibrillation (n  2), unexplained mental status
changes (n  2), septicemia (n  2), and urinary inconti-
Thoracic aortic pathology disease treated with stent grafts
Degenerative aneurysm 18
Chronic dissection 4
Pseudoaneurysm 3
After trauma 1
Anastomotic 2
Intramural hematoma 2
Coarctation restenosis 1
Total 28
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Stent graft repair of complex thoracic aortic pathology. Patient was frail 82-year-old woman who had recently
undergone suprarenal open AAA repair complicated by retrograde intraoperative aortic dissection. Rapid enlargement
of thoracic aorta with dissection superimposed on degenerative aneurysm was noted with significant back pain and
documented expansion from 4 to 6.5 cm during 4-month interval. A, Axial computed tomographic (CT) images show
dissection channel (arrow) in 6.5-cm aneurysm. B, Intraoperative angiogram shows proximal deployment site (large
arrow) just distal to left subclavian artery (double arrows). C, Intraoperative angiogram shows distal deployment site
(single arrow) into origin of celiac axis (double arrows). D, Postoperative axial CT scan (same level as A) documents
aneurysm sac collapsed around stent graft. E, CT scan reconstruction shows two 40-mm interlocking stent grafts
excluding entire thoracic aorta to level of celiac axis (arrow).
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nence (n  2). Notably, no strokes and no spinal cord
ischemic complications were seen.
Anatomic follow-up examination. Among 19 pa-
tients treated for degenerative aneurysm (including one
patient with dissection in a recognized antecedent degen-
erative aneurysm), CAT scan follow-up imaging data were
available for a mean interval of 11 months after treatment.
Aneurysm sac shrinkage was observed in nine patients
(47%), and no aneurysms were noted to enlarge. Delayed
development of endoleak or graft migration was not ob-
served; stent graft extension either proximally or distally has
not been necessitated.
DISCUSSION
Experience in the current modest-size series supports
the feasibility, safety, and (with important qualifications
about follow-up duration) efficacy of stent graft repair for
degenerative descending TA aneurysm. Although far less
common than degenerative aneurysm in the infrarenal po-
sition, both the proportionally higher risk of conventional
operation for TA disease and the possibility of extending
stent graft repair to the treatment of acute distal dissec-
tion8,9 is certain to increase demand for this technology. In
contrast to other reported series,4,7,10-12 ours is a com-
bined experience with the so-called first generation device
(Dacron over Gianturco Z stent endoskeleton) and the
W.L. Gore Excluder graft, affording an opportunity to
assess the capabilities and limitations of each construct. We
certainly agree that there are distinct disadvantages of the
custom-made construct—large caliber delivery systems,
lack of flexibility, segmented design prone to kinking in
curved aortic segments, inaccuracy of proximal deploy-
ment—as emphasized elsewhere.4,10 The proprietary de-
vice we used in 14 patients is clearly a superior design. Yet
the custom-made construct continues to have a role partic-
ularly in focal disease in the straight portion of the descend-
ing aorta and until such time as proprietary devices have
completed the cycle of clinical trial and eventual approval.
Indeed, as of the writing of this report, the W.L. Gore
Excluder device is “on hold” because of stent fractures
(none were observed in our patients) leading in at least one
case to device failure and TA rupture.
Although the cumulative experience with thoracic stent
graft repair is limited, important distinctions from the
parallel experience with AAA stent graft repair are apparent.
First, periprocedural mortality rate with TA stent graft
repair generally exceeds that reported for abdominal aortic
stent grafting. The 3.5% operative mortality rate reported
herein is significantly higher than our recently reported
experience with 362 AAA stent graft repairs (operative
mortality rate, 1.6%).14 Yet this 3.5% figure is at the lower
range reported for TA stent graft repair, with other reports
noting procedural mortality rate in the 9%4 and even up to
the 20% range.10 These figures are influenced by the fact
that most TA stent series contain small numbers of patients
and many of these have been treated in truly desperate
anatomic or clinical circumstances wherein conventional
open operation was not a realistic option. Despite such
mitigating factors, also clear is that direct device-related
problems have contributed substantially to procedural
mortality. Device migration with aneurysm rupture,13 de-
vice failure with immediate open conversion,10,12 massive
distal embolization,7,10 fatal mesenteric ischemia from ce-
liac occlusion,13 and stroke from device manipulation in the
aortic arch4 have all been reported. Inaccurate proximal
deployment (particularly when proximal fixation is at or
near the aortic arch) caused by the “wind sock” effect of
ventricular ejection figured prominently in the failures and
complications reported with first generation devices.4,10
Superior design characteristics of second generation devices
have already made intraoperative maneuvers, such as induc-
ing ventricular asystole during graft deployment, obsolete.
Despite this fact, we agree with the intuitively logical con-
clusions of other authors that careful preoperative anatomic
assessment, including a qualitative assessment (for mural
debris) of device landing zones, and ensuring adequate
proximal and distal fixation lengths are essential in avoiding
potentially fatal procedural mishaps.10 To achieve such
adequate proximal fixation, no hesitation should be seen in
initiation of the procedure with left subclavian artery trans-
position, a maneuver necessary in some 20% of our patients
and in 8% to 43% in other reports.4,10,13 We strongly
disagree with the posture of simply covering the left sub-
clavian origin with the stent graft or deploying the same
into the origin of the subclavian artery.15 Although sacrifice
of the subclavian will be tolerated by most, if not all,
patients, the concern for devastating proximal endoleak is
too great to forego the simple expedient of left subclavian
transposition.
Two additional procedural complications, namely ac-
cess artery issues and spinal cord ischemia, are deserving of
comment. Given that large-diameter introducer systems are
typically necessitated and the higher relative (compared
with AAA) proportion of female patients (with expected
smaller iliofemoral arteries) with thoracic aneurysm,2,16
access artery constraints and potential complications can be
anticipated in many candidates for TA stent grafting. The
approximately 20% rate of something other than trans-
femoral access is in the range (16% to 66%) reported in
other series,4,10,13 although these figures are influenced by
inclusion of patients who have undergone simultaneous
open AAA repair with use of the abdominal graft for TA
stent graft access. Careful consideration of complete preop-
erative pelvic vessel imaging studies is necessary to develop
an appropriate operative plan. There should be no hesita-
tion to directly approach iliac vessels or the abdominal aorta
when mismatch between delivery system size and femoral/
external iliac artery size exists. Furthermore, intraproce-
dural maneuvers, such as preemptive placement of balloon
occlusion catheters before sheath withdrawal, can be life-
saving in the circumstance of iliofemoral artery disruption,
which typically occurs at the iliac bifurcation and is recog-
nized only as the delivery sheath is removed at the conclu-
sion of the procedure. Access artery complications, which
occurred in some 20% of our patients and caused the only
operative death, must be both anticipated and managed
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promptly. The potential for such complications constitutes
a compelling argument for continued use of general anes-
thesia, arterial-line monitoring, and a fully equipped oper-
ating room as the appropriate environment for TA stent
graft procedures.
As experience accumulates, a gratifying dearth of spinal
cord ischemic complications accompanying TA stent graft-
ing has been seen. Although such complications have been
reported,4,7,10,17 experience to date permits the conclusion
that the usual surgical paradigm relative to intercostal vessel
sacrifice during open repair18 and its resultant increased risk
of spinal cord ischemic complications does not pertain to
stent graft repair. We observed no spinal cord complica-
tions despite the fact that many of our patients had the
critical lower thoracic segment (ninth thoracic vertebrae to
first lumbar vertebrae) completely covered with the stent
graft. In addition, three patients underwent concomitant
open AAA repair, a circumstance that apparently increases
the risk of cord ischemia in the Stanford experience.
Whether related to aortic crossclamp application or con-
comitant sacrifice of lumbar arteries, the Stanford group
noted lower extremity neurologic deficit only when con-
comitant open AAA repair was performed; accordingly,
they recommended against simultaneous repair.4 Not sur-
prisingly, Greenberg et al10 correlated more extensive
lengths of stent grafts as increasing cord ischemic compli-
cations, which they observed in 12% of their patients.10
This latter figure must be considered a maximum for spinal
cord complications because most reports are similar to our
own experience with cord ischemia in the 0 to 3%
range.4,7,13 One group suggested a test deployment of a
collapsable stent graft with evoked potential monitoring to
assess the potential negative impact of stent graft exclusion
of intercostal vessels.19 Also suggested is that patients at
high risk for cord ischemia undergo management with
protective adjuncts (cerebrospinal fluid [CSF] drainage,
hypothermia, etc) as might be used during open repair.7
We did use CSF drainage in a single patient deemed at high
risk for cord ischemia (Fig); the patient did well, but the
impact of CSF drainage is, of course, unknown. Although
no definitive statements about the comparative risks of
spinal cord ischemia with open versus stent graft repair are
possible, the available evidence, including the present ex-
perience, suggests that the risk of cord ischemia with stent
graft repair is low.
Efficacy of TA stent graft repair will only be proven
when sufficient numbers of treated patients are followed for
long periods of time. Currently, intermediate range fol-
low-up is available for small numbers of patients in this
study and in other reports.4,10 We have assumed that
absence of endoleak associated with aneurysm sac shrinkage
or stability represents successful treatment; indefinite radio-
graphic follow-up is clearly indicated. Endoleak with TA
stent graft repair is usually of the so-called type I (ie,
attachment site) variety and, not surprisingly, is usually
associated with treatment failure.4,10,13 Similar to our find-
ings and in contrast to the experience with AAA stent graft
repair, Greenberg et al10 commented on the scarcity of type
II endoleak as a persistent problem.10 These authors also
cautioned that sac shrinkage should be expected in success-
fully treated cases. Resch et al20 documented mean aneu-
rysm shrinkage of just 4 mm at an 18-month mean fol-
low-up period.20 We noted shrinkage on computed
tomographic scans at 1 year in some 50% of patients. White
et al7 noted aneurysm sac volume to be decreased or stable
in most patients after stent graft repair, and this method
may be the more sensitive and preferred method of fol-
low-up examination.7 Late migration of the stent graft,
particularly as the aneurysm morphology changes after
exclusion, has been a cause of late failure and correlated
with graft kinking by two groups.4,20 This phenomenon
has been observed primarily with the first generation con-
struct especially when graft kinking occurs. Late migration
of the stent graft has not been observed in our patients, nor
are endoleaks persistent in our patients currently under
observation.
This series mirrors the experience of other investigators
in terms of patient anatomic selection and device evolution.
We attribute the favorable results reported herein to a
reluctance to compromise on anatomic constraints (insist-
ing on a minimum 2-cm fixation length and avoiding
tortuous aortic segments as fixation points), particularly
with the first generation construct. The accumulating ex-
perience with TA stent graft repair indicates that it will be
an effective alternative to open repair for degenerative
aneurysm in patients with suitable anatomy. Exciting de-
velopments with TA stent graft repair for acute distal dis-
sections and chronic dissection with aneurysm have been
reported.7,8 Prospective trials for each of these individual
diseases will be necessary before the ultimate role of TA
stent grafting is defined.
Note: Since the submission of this material, a recent
case of extensive thoracic stent graft replacement has been
complicated by paraplegia.
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DISCUSSION
Dr Robert Hopkins (Providence, RI). I greatly admire the
study and its presentation. It seems almost miraculous. I have two
questions. One is the question of how many patients you found
unacceptable for this procedure and used the open technique by
preference? Second, with respect to spinal cord ischemia, what
proportion of your patients had very limited stents and how many
actually covered most of the thoracic aorta with the intercostal
vessels included?
Dr Richard Cambria. Thank you, Dr Hopkins, for your
comments and questions. I will answer your second question first.
You obviously made the sage observation that one of the available
series in the literature has correlated, as you might expect, increas-
ing lengths of the thoracic aorta covered with an increase in risk of
spinal cord ischemia. We had nine patients who had most or all of
the descending aorta covered in this experience. The remainder of
the patients, 19, had relatively focal lesions that could be encom-
passed by a graft no longer than 15 cm.
With respect to your first question, we do approximately 60 to
70 thoracic or thoracoabdominal aneurysm repairs on our service
annually. This is an experience that began in late 1996. I do not
have the exact comparative numbers for you, although I will tell
you that in the course of the phase 2 clinical trial for the Gore
excluder device, this was a protocol that basically mandated equal
numbers of open conventional operation controls to stent graft
patients. So, for those 11 patients during this study interval, there
were 11 open thoracotomy repairs of descending thoracic aneu-
rysms. In terms of a numerator/denominator sort of equation, if
you take the entire spectrum of thoracic thoracoabdominal aneu-
rysm disease, the percentage of patients graftable with this tech-
nology is certainly going to be lower than the corresponding
abdominal aneurysm numbers because as aneurysms extend into
the visceral aortic segment they of course are not treatable with
stent graft repair.
Dr Philip Allmendinger (Hartford, Conn). Congratula-
tions to Dr Cambria on this wonderful exposure of what is going
on with the stent grafts in the thoracic aorta.
We had one experience with a patient in her late 70s who had
had an abdominal aneurysm repair, and we extended the thoracic
excluder graft down to the celiac. She had transient ischemia,
which was manifested simply by numbness and weakness intermit-
tently for about 6 weeks. This subsequently resolved. My question
is, in the chronic dissection, did you have any visceral vessels
coming off the false lumen and what was the result of excluding the
false lumen with the stent graft?
Dr Cambria. Thank you for your comment and observation.
I do not mean to imply (although we had 28 patients here with no
ischemic spinal cord complications) that spinal cord ischemia is
solved, and it certainly has been reported with stent graft repair in
the thoracic aorta. The incidence rate ranges from a low of 0 to a
high of 9% in those few series available. The patient that you asked
about with the chronic dissection aneurysm is a complicated one.
Because all visceral vessels below had already been reconstructed
with an open repair, there was no potential for eliminating perfu-
sion of vessels perfused from a false lumen.
Dr Richard Powell (Lebanon, NH). Those results are quite
impressive. I had two questions. One was that I know that the Gore
balloon is lobulated to allow flow around the balloon while it is
inflated to facilitate precise placement in the proximal portion of
the graft. I was wondering what other techniques your group used
to facilitate precise placement of the proximal portion of the graft.
The other question I had was related to the iliac perforations,
whether you thought these perforations would be amenable to
repair with a covered graft like a Wallgraft or one of the AneuRx
limb grafts.
Dr Cambria. Thank you, Dr Powell, for your questions.
With respect to the iliac artery disruptions, we have learned in the
course of some pretty heated and uncomfortable moments how to
get ready to anticipate that. Firstly, when you are introducing
hardware going in, one develops a feel for just how tight that is,
and even if you have a centimeter-wide external iliac artery in a nice
size man, the 24F Keller Timmerman sheath fits pretty tight in just
about everybody. If you have issues referable to the iliac arteries, we
have gotten into the habit of placing a balloon in the very proximal
common iliac artery as the sheath comes out so that you can be
prepared to inflate that. Whether or not it would be reconstructible
with a covered stent graft I think relates to the extent of the injury.
We have not done that; we have simply opened the retroperito-
neum and fixed it. The most common site of injury is at the iliac
bifurcation where the common iliac gives off the external. That is
usually where the disruption occurs, so it would at least in theory
be possible to fix that with proximal balloon control and a covered
stent graft from the common iliac to the more distal external iliac.
Your first question was about maneuvers with respect to
proximal deployment accuracy, in particular with the second gen-
eration devices. The era of adenosine or fibrillation to arrest the
heart and so forth has gone by. It is very important to drive your
introducer wire so that the graft hugs the outer curvature of the
transition from the arch to the proximal descending aorta. One can
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then affix the graft to prevent foreshortening at the lesser curva-
ture. We do drop the systolic blood pressure to the 70-mm,
80-mm range when we have to deploy in the transverse portion of
the arch. As mentioned, the deployment mechanism of the Gore
excluder device has pretty much eliminated many of those con-
cerns about accuracy of proximal deployment.
Dr Jens Jorgensen (Portland, Me). I would like to add a very
nice presentation on an elegant solution to a complex problem.
Just a couple of questions.
Do you use any of the usual adjuncts for spinal cord protec-
tion, such as spinal cord drainage or barbiturates or whatever?
Secondly, would you mind speculating on why you think
covering the intercostals does not lead to spinal cord ischemia?
Dr Cambria. Thank you for your questions. My speculation
is that the usual surgical paradigm does not hold because, although
you are eliminating intercostal vessels that are potentially contrib-
uting spinal cord blood supply, you are not doing all the other
things like crossclamping the aorta, sacrificing potential collateral
circulation, and so forth.
As regards the patient with the complex pathology, combined
dissection, and degenerative aneurysm, who was going to have her
entire descending aorta covered to a prior graft that had been placed
3 months previously, I did use CSF drainage and kept her in an in-
tensive care unit for 48 hours with CSF drainage. The patient had no
problems. Of course we do not know if that adjunct was at all effective,
but that we have used it in a single case is the answer to the question.
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